Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation therapies in immuno-oncology and immuno-inflammation. The company focuses on harnessing microbiome-associated innate immune regulatory mechanisms to enhance patient's responsiveness to treatments in conditions where dysregulated immunity hampers efficacy, including inflammatory bowel diseases, solid tumor cancers and some infectious diseases.

Exeliom Biosciences

Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness microbiome-associated innate immune regulatory mechanisms.

European Innovation Council

Bpifrance

INRA

Sofimac Innovation

Auriga Partners

Biocodex

Cap Innov'Est

UI Investissement

Capital Grand Est

CE-Ventures

🗞️ Exeliom in the News!
 
Roohi M.'s in depths piece for Labiotech.eu highlights the groundbreaking advancements in therapies for Inflammatory Bowel Disease (IBD). 
 
The article showcases the evolving landscape of IBD treatments and our vibrant biotech community. Collaboration and innovation within our industry fuels our mission to deliver cutting-edge solutions and reinforces our dedication to improving patient outcomes. 
 
🔬 IBD is a chronic condition that includes Crohn's disease and ulcerative colitis, characterized by inflammation of the gastrointestinal tract. Affecting millions worldwide, IBD can cause severe symptoms such as abdominal pain, diarrhea, and fatigue. Traditional treatments often fall short, underscoring the necessity for breakthrough therapies.
 
🤝 Our lead candidate, EXL01, is at the forefront of this innovative approach. We're thrilled to be collaborating with REMIND Group on the MAINTAIN POP clinical trial, further exploring the potential of EXL01. This partnership represents a significant step towards a more effective and targeted therapy. 
 
Together, let's continue pushing the boundaries of science to improve lives and combat IBD.
 
Read the full article here 
https://lnkd.in/e-Kyt9DY
 
#IBD #Innovation #Biotech #Microbiome #Research #CrohnsDisease #UlcerativeColitis #GutHealth

🚀 What sets Exeliom apart ? 🚀
 
We're redefining resilience and innovation in therapeutic development!
 
🔬 The Science: Based on scientific discoveries and research in microbiota by our co-founders, Prof. Harry Sokol, Dr. Philippe Langella, and Prof. Patrick Gervais, our scientific team has developed our lead candidate, EXL01, a remarkable live biotherapeutic product (LBP) with promising applications as both a stand-alone and adjuvant treatment for a variety of diseases. EXL01 is currently being investigated in several clinical trials in immuno-oncology, Crohn’s disease, and recurrent Clostridioides difficile infection.
 
👩🔬👨💼The Team: Our team of 7 FTEs is dedicated to the advancement of Exeliom’s lead candidate by securing partnerships, funding and collaboration within the industry. Our small size ensures flexibility and efficiency. It has allowed us to successfully launch four clinical trials in 2024 alone with more to come. Additionally, our effective remote work system enables our team to operate across France, Europe, and beyond, with the goal of maximizing productivity and collaboration.
 
🤝 The Collaborations: For each of our clinical trials, Exeliom's team has organized collaborations with leading institutions and industry partners. These have been crucial in enhancing our research capabilities, ensuring high-quality trial execution, and accelerating our path to therapeutic breakthroughs. This year alone, Exeliom has been able to collaborate with leading academic institutions including Hospices Civils de Lyon - HCL, GERCOR, CHU de Lille, the Centre Eugène Marquis, and REMIND Group.
 
🛡️ Our Crisis-Proof Model: Our innovative operational approach, under the leadership of Benjamin Hadida, our CEO, has enabled us to prove resilient against significant crises. For starters, we weathered the burst of the biotech bubble between 2021 and 2023 and the challenges posed by conducting research during COVID-19. Another example is our first clinical trial, which was supposed to take place in Ukraine. When the war broke out in February 2022, we were able to rapidly change gears and relocate our operations, ensuring continuity and progress. While many in the microbiome field faltered, our resilient model allowed us to thrive and continue advancing our mission.
 
Read more here: https://www.exeliombio.com
 
#Innovation #Biotech #Inflammation #ClinicalTrials #Microbiome 🌍✨

🌟 Clinical Trial News! 🌟

The first patient has been dosed in another clinical trial evaluating our lead candidate EXL01 in the treatment of cancer! Following the enrolment in the BIG trial announced last week in gastric cancer, this week we can also confirm that we have our first patient in the EXLIBRIS clinical trial in lung cancer! In the EXLIBRIS study EXL01 will be evaluated in second line, in combination with nivolumab, the same immune-checkpoint inhibitor already used in the BIG study. As 1 in 16 people can expect to be diagnosed with lung cancer in their lifetime, the importance of this trial cannot be understated.

EXLIBRIS study is one of three complementary clinical trials that are being conducted in parallel  to demonstrate the potential of EXL01 in immuno-oncology when combined with checkpoint inhibitors.

We extend our sincere thanks to the outstanding team leading the trial at the CHU de Lille, listed as one of the top five university hospitals in France for the quality of its research.

🔗 Learn more about the what we do here:

www.exeliombio.com

#CancerResearch #ClinicalTrials #Oncology #NSCLC #LungCancer #Microbiome

🌟 Clinical Trial Update! 🌟

Exeliom is happy to report that the first participant has been enrolled in our BIG clinical trial in immuno-oncology! This crucial study investigates the efficacy of EXL01 as an adjuvant in the treatment of gastric cancer. With almost one million new cases diagnosed each year, this is a major research area that demands effective and accessible treatment.

We would like to thank GERCOR for leading the trial. As a non-profit organization with a network of over 300 centers, its mission is to improve treatments for solid tumor cancer patients.

🔗 Stay tuned for further updates and learn more about our lead candidate here:

www.exeliombio.com

#CancerResearch #ClinicalTrials #Oncology #GastricCancer #Microbiome

📅 Save the Date!

Don’t miss Professor Harry Sokol, co-founder of Exeliom, speaking at the 16th World Congress on Inflammation from July 21-24 in Quebec. 🇨🇦

🔬 This congress gathers leading experts to discuss the important advances in inflammation science, featuring keynote presentations, workshops, and panel discussions on the latest research and therapeutic strategies.

💡 Professor Sokol will present on Exeliom's pioneering lead candidate, EXL01, which harnesses microbiome-associated innate immune regulatory mechanisms to enhance patient responses in conditions where dysregulated immunity impedes treatment efficacy. By leveraging these mechanisms, EXL01 can be used as a stand-alone or adjuvant treatment to combat inflammation in a variety of conditions including inflammatory bowel diseases, solid tumor cancers, and certain infectious diseases.

🔍 Explore the potential benefits of Exeliom’s approach to improve patient outcomes with Harry’s insights from the congress.

https://ow.ly/KsTr50SC80n

#Inflammation #HealthcareInnovation #Microbiome #Research

💬 During BIO 2024, Benjamin Hadida, our CEO, sat down with Janelle Hart from Citeline to discuss our pioneering work in immuno-oncology and immuno-inflammation.

🔬Our first-in-class drug candidate, EXL01, utilizes Faecalibacterium prausnitzii (F. prau) to leverage the power of gut bacteria to enhance therapeutic responsiveness across immuno-oncology, immuno-inflammation and rare diseases, to predict and boost treatment efficacy, offering a new paradigm in microbiome-based approaches.

💡Benjamin shared how his journey led to the co-founding of Exeliom and the driving force behind his desire to bridge the gap between the business and scientific worlds, with the aim of bring impactful innovations directly to patients. 

🔗 Full article available here to subscribers: https://lnkd.in/edHY5SBi

#Immunotherapy #Microbiome #Biotech #Innovation #BIO2024

🔬New scientific publication on our lead candidate🔬

We are excited to share that our latest research on EXL01, undertaken by our co-founder Prof. Harry Sokol, has been published in OncoImmunology. 

Harry explains in his post the key highlights of this paper. You should definitely read this below.

Full research paper available here: 
https://lnkd.in/eQxF4t63

A big thank you to the team and our partners for their unwavering support and hard work.

#Research #EXL01 #Innovation #Healthcare #Science #Oncology
#CancerResearch

🌍 Happy World Microbiome Day!

Today, on #WorldMicrobiomeDay, Exeliom is proud to be a part of the international community celebrating the remarkable world of microbiomes. These tiny, yet powerful, microorganisms play a crucial role in everyone’s health, and we are excited to harness their potential to change lives.

💥 At Exeliom Biosciences, we advance microbiome science through innovative research and development. Our lead candidate, EXL01, is a live biotherapeutic product that contains an unmodified single-strain of F. prausnitzii, a key player in the human gut microbiome, to treat diseases and improve health outcomes.

🧑🔬By leveraging the natural functions of these microorganisms, we aim to provide treatments that can change the lives of patients living with a variety of diseases including Inflammatory Bowel Disease and cancer.

On this special day, we celebrate the progress made by scientists and researchers in this fascinating field 👏 

#Microbiomes4life #Microbiome #Innovation #Biotech #IBD #Oncology #Crohns

📢 Collaboration alert!

We're working with REMIND, a renowned consortium of 14 French gastroenterology departments, onthe MAINTAIN POP study, a pivotal Phase II trial evaluating our lead candidate, EXL01, in preventing post-operative recurrence in Crohn’s disease patients.

🤝 This was made possible by Pr. Matthieu Allez, REMIND’s co-founder and president, and underscores our commitment to advancing innovative treatments for inflammatory bowel disease (IBD).

🧬 Building on the positive safety profile observed in the MAINTAIN Part A study, EXL01 - a live biotherapeutic product featuring an unmodified single-strain of F. prausnitzii - shows great promise as an immuno-modulating medicine targeting the gut microbiome.

🔬 The trial will enroll 80 patients who have achieved remission through surgery, aiming to provide critical insights into EXL01's potential to enhance post-surgery quality of life. We anticipate topline results in Q1 2027.

🔗 https://lnkd.in/dsDqbmTS

#Crohns #ClinicalTrials #IBD #Gastroenterology #Innovation #Microbiome

🌟 Save the date! 🌟

We are thrilled to share that Professor Harry Sokol, Exeliom’s co-founder, has been invited to speak at this year’s IHMC 2024, June 22-25 in Rome! 🇮🇹

🔬 The International Human Microbiome Consortium (IHMC) is a global forum bringing together leading experts to discuss cutting-edge research in microbiome science. This year's conference will cover a wide range of topics, including the interaction between human microbiota and health, and novel therapeutic approaches.

🧬 Professor Sokol will be presenting unpublished data on our lead candidate, EXL01, and its groundbreaking potential in immuno-oncology. This is a significant milestone for Exeliom Biosciences, as we continue to explore innovative therapies that harness the power of the microbiome to revolutionize cancer treatment.

🤝 Make sure you don’t miss Harry Sokol’s presentation and stay tuned for more updates and insights from IHMC 2024!

https://ihmc2024rome.com

#IHMC2024 #ImmunoOncology #Microbiome #Innovation #CancerResearch

EXEL

COM:EXELIOMBIO

Exeliom Biosciences